COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

LYMPHOMA RESEARCH FOUNDATION
NEW YORK, NY · EIN 954335088 · Form 990 · FY2024 · NTEE G80 · Voluntary Health Associations · Large ($10M-$50M) · lymphoma.org
revenue
$14.2M
expenses
$14.3M
net assets
$34.5M
employees
47
volunteers
20,000
program ratio
72%
mission · from form 990

TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE.

profile · synthesized from sources

The Lymphoma Research Foundation is dedicated to eradicating lymphoma and serving those affected by the disease through research funding, patient education, and advocacy. The organization supports scientific innovation by funding early-career researchers and facilitating collaboration across academia, industry, and regulatory bodies. It also provides comprehensive support services, educational resources, and policy advocacy for patients and healthcare professionals nationwide.

irs program accomplishments · form 990 part iii · fy2024

What they reported doing

  1. #1 primary $3.91M
    RESEARCH AND SCIENTIFIC PROGRAMS - THE LYMPHOMA RESEARCH FOUNDATION'S RESEARCH PROGRAM IS GUIDED BY ITS ELITE SCIENTIFIC ADVISORY BOARD, COMPRISED OF 45 EXPERT LYMPHOMA CLINICIANS AND SCIENTISTS FROM ACROSS NORTH AMERICA. THE FOUNDATION FUNDS RESEARCH INVESTIGATING EVERY LYMPHOMA SUBTYPE AND REMAINS COMMITTED TO SUPPORTING EARLY CAREER SCIENTISTS TO ENSURE THE BEST AND BRIGHTEST SCIENCE MINDS ARE DEDICATED TO RESEARCHING LYMPHOMA. IN ADDITION TO DIRECTLY FUNDING RESEARCH GRANTS, THE FOUNDATION FACILITATES COLLABORATION AND PARTNERSHIPS AMONG ACADEMIC SCIENTISTS, CLINICIANS, INDUSTRY, REGULATORY AGENCIES, AND PATIENTS. THROUGH ITS GLOBAL LYMPHOMA CONSORTIA AND SCIENTIFIC WORKSHOPS, THE FOUNDATION MOBILIZES THE RESEARCH COMMUNITY TO OVERCOME SYSTEMIC CHALLENGES AND SPEED THE PROGRESS OF THE DEVELOPMENT OF NEW TREATMENTS AND UNDERSTANDING OF THE VARIOUS SUBTYPES OF LYMPHOMA.
  2. #2 $1.72M
    COMMUNITY OUTREACH AND ADVOCACY - THE LYMPHOMA RESEARCH FOUNDATION'S FOCUS INCLUDES COMMUNITY-BASED, PATIENT-CENTERED EDUCATION AND OUTREACH; INCREASING REPRESENTATION IN LYMPHOMA RESEARCH AND CLINICAL CARE AND COALESCING THE LYMPHOMA COMMUNITY AROUND AWARENESS INITIATIVES FOR THIS RARE DISEASE. THE FOUNDATION IS COMMITTED TO ADVOCATING ON BEHALF OF THE ENTIRE LYMPHOMA COMMUNITY IN SUPPORT OF THIS MISSION, WORKING COLLABORATIVELY WITH POLICYMAKERS, MEDICAL COMMUNITY, PATIENT ADVOCATES AND OTHER STAKEHOLDERS TO ADVANCE EFFORTS THAT WILL IMPROVE THE LIVES OF PEOPLE WITH LYMPHOMA. THE FOUNDATION SUPPORTS MEASURES WHICH WILL INCREASE FEDERAL FUNDING FOR LYMPHOMA RESEARCH AND ENSURE PATIENT ACCESS TO HIGH QUALITY CANCER CARE AND IMPROVED ANTI-CANCER TREATMENTS. THE FOUNDATION ALSO SUPPORTS EDUCATION AND OUTREACH EFFORTS TO IDENTIFY AND REACH UNDERSERVED PATIENT POPULATIONS.
named programs · 5 · from sources

What they call their work

Community Outreach and Advocacy
Conducts patient-centered outreach, promotes diversity in clinical trials, advocates for increased federal research funding, and works to improve access to high-quality cancer care.
Continuing Medical Education
Delivers educational activities for healthcare professionals to enhance knowledge and improve the quality of lymphoma care.
Educational Programs and Support Services
Offers in-person and virtual education forums, disease-specific publications, a mobile app, and a helpline providing individualized support to patients and caregivers.
Lymphoma Helpline
Provides personalized support and answers lymphoma-related questions for patients and their loved ones.
Research Programs
Funds lymphoma research across all subtypes, supports early-career scientists, and convenes scientific consortia and workshops to accelerate treatment development through collaboration among researchers, clinicians, industry, and regulators.
activities · 5 groups

What they do

  • Healthcare Policy Advocacy 1 activity
    • Advocating for policy changes to improve lymphoma care and research funding
      Engages in advocacy to increase federal investment in lymphoma research and ensure patient access to high-quality cancer care. Supports legislation such as the Comprehensive Cancer Survivorship Act and collaborates with policymakers and stakeholders to promote policies that accelerate treatment development and support survivors.
  • Mentorship and Professional Development Programs 1 activity
    • Building research capacity through mentorship and collaboration
      Strengthens the lymphoma research field by providing mentorship, scientific guidance, and networking opportunities for early-career investigators and fellows. Operates the Lymphoma Scientific Research Mentoring Program (LSRMP), offers faculty-led workshops connecting emerging scientists with established leaders, and facilitates access to expertise on topics such as the follicular lymphoma immune microenvironment.
  • Biomedical Research and Innovation 1 activity
    • Conducting and supporting original lymphoma research
      Directly conducts or supports targeted scientific research initiatives, including long-term clinical trial follow-up (e.g., SWOG S0016), investigations into immunotherapy enhancement via macrophage targeting, and studies on reducing CAR T-cell therapy toxicities. Research outputs include peer-reviewed publications such as in Nature Communications and contributed to FDA approval pathways for new therapies.
  • Cancer Research Funding 1 activity
    • Funding lymphoma research through competitive grants
      Awards and manages scientific research grants to advance understanding, diagnosis, and treatment of all lymphoma subtypes. In recent years, awarded 24 grants totaling up to $3.9 million annually and has committed over $86 million in research funding since inception. Supports projects across academic and medical institutions, including those focused on macrophage biology, CAR T-cell therapy toxicities, follicular lymphoma outcomes, and novel treatments like sonrotoclax for mantle cell lymphoma.
  • Disease-Specific Clinical & Patient Education 1 activity
    • Providing comprehensive educational programs and resources for patients and caregivers
      Offers a wide range of disease-specific education through virtual and in-person formats, including bi-monthly two-hour sessions, annual two-day conferences, webinars, and supportive care workshops. Provides multilingual materials and programming, including Spanish-language support and interpretation services. Produces publications covering lymphoma basics, subtypes, treatment options, survivorship, and follow-up care, distributed via a Lymphoma Resource Center and self-paced platforms.
financials · form 990 · fy2024
revenue
Total revenue$14.18M
Contributions & grants$8.90M63%
Program service revenue$3.73M26%
Investment income$1.48M10%
Other revenue$65K
expenses
Total expenses$14.31M
Program expenses72%
Admin / overhead13%
Fundraising15%
Salaries & benefits$5.42M
Grants paid out$2.86M
Largest expense lineCompensation
balance sheet
Total assets$42.72M
Cash$3.97M
Investments$36.39M
Liabilities$8.19M
Net assets$34.53M
Liquid reserves33.9 mo
6 years on record · 2019–2024 · YoY revenue +1.8%
leadership · form 990 part vii · fy2024

Who runs it

paid leadership · 9
NameTitleHours/wkCompensation
MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 45 $383K
LAURA WALLENSTEIN CHIEF PHILANTHROPY OFFICER 35 $280K
SARAH QUINLAN CHIEF PROGRAM OFFICER 35 $237K
CHRISTA BOGGIO CONTROLLER 45 $208K
NICHOLAS GUERCIO SENIOR DIRECTOR, MARKETING & COMMUNICATION 35 $194K
VICTOR GONZALEZ SENIOR DIRECTOR, PATIENT PROGRAMS 35 $191K
MICAH BANNER SENIOR DIRECTOR, INDIVIDUAL GIVING 35 $181K
LYNNE WINTER SENIOR PHILANTHROPIC ADVISOR 28 $168K
HILLEL HYMAN CHIEF OPERATING OFFICER (EFF. 12/2024) 35 $15K
board members · 16
  • ANN LACASCE MD MMSC — BOARD MEMBER
  • ELLEN WALKER — BOARD MEMBER (EFF. 2/2025)
  • HARRIET GREENBERG — BOARD MEMBER
  • JEFF BLOCK — VICE CHAIR AND TREASURER
  • JOEL POLLICK — BOARD MEMBER
  • JOHN A NELSON — BOARD MEMBER
  • JOHN P LEONARD MD — BOARD MEMBER
  • KEVIN SHEA — BOARD MEMBER
  • KIM METCALF — VICE CHAIR
  • KRISTI HENDRIKS — BOARD MEMBER (EFF. 7/2024)
  • LAURENCE DOBOSH — BOARD MEMBER
  • LEIGH OLSEN — SECRETARY
  • LINDSAY SPRINGER — BOARD MEMBER
  • MICHAEL FROY — BOARD MEMBER
  • MICHAEL WERNER — BOARD MEMBER
  • PATRICIA KANE — BOARD MEMBER (EFF. 6/2025)
relationships · 27

Who they work with

  • City of Hope Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Condon Family Foundation Partner — Collaborates with the Lymphoma Research Foundation to fund research initiatives and support long-term strategic investments in lymphoma science.
  • Dana-Farber Cancer Institute Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Grady Health System Partner — Collaborates with Grady Health System on patient education and outreach initiatives.
  • Icahn School of Medicine at Mount Sinai Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Lymphoma Support Network Partner — Provides peer support services as part of the Lymphoma Resource Center.
  • Massachusetts General Hospital Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • McMaster University Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Memorial Sloan Kettering Cancer Center Partner — Host institution for multiple Lymphoma Research Foundation grant recipients conducting funded lymphoma research.
  • NYU Grossman School of Medicine Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Rutgers Cancer Institute Partner — Institution affiliated with the Chair of the Foundation's Scientific Advisory Board.
  • SWOG Partner — Collaborated on the S0016 clinical trial to study long-term outcomes in follicular lymphoma treatment.
  • Scientific Advisory Board Network — Comprised of 45 international lymphoma experts who lead the grant selection process
  • Scientific Advisory Board Partner — Comprised of 45 expert lymphoma clinicians and scientists who guide the Foundation's research program.
  • The Ohio State University Partner — Host institution for multiple Lymphoma Research Foundation grant recipients conducting funded lymphoma research.
  • The Trustees of Columbia University in the City of New York Partner — Host institution for multiple Lymphoma Research Foundation grant recipients conducting funded lymphoma research.
  • The University of Texas MD Anderson Cancer Center Partner — Collaborates with the Lymphoma Research Foundation through researcher affiliation and clinical research
  • The University of Texas MD Anderson Cancer Center Partner — Host institution for multiple Lymphoma Research Foundation grant recipients conducting funded lymphoma research.
  • The University of Texas Southwestern Medical Center Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • U.S. Food and Drug Administration Government — Regulatory agency that approved sonrotoclax for mantle cell lymphoma
  • University of Washington Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Vanderbilt University Medical Center Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Washington University in St. Louis Partner — Host institution for a Lymphoma Research Foundation grant recipient conducting funded lymphoma research.
  • Weill Cornell Medical Center Partner — Host institution for a Foundation-funded researcher and site of clinical and scientific collaboration.
  • Weill Cornell Medical College Partner — Institution where a Foundation-funded researcher trained in oncology and lymphoma.
  • Yale University Partner — Host institution for multiple Lymphoma Research Foundation grant recipients conducting funded lymphoma research.
  • lymphoma experts Partner — Collaborates with lymphoma experts to lead educational programs and provide clinical information.
strategies · 4

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Cross-Sector Research Acceleration
    methodology: cross_sector_collaboration
    By convening collaborations across researchers, clinicians, industry, regulators, and patients, the foundation accelerates therapeutic development, because multi-stakeholder alignment breaks down silos and drives faster translation of research into treatments.
  • Cultivation of Early-Career Scientists
    methodology: mentorship_integrated_grantmaking
    By providing integrated grant funding and mentorship to early-career researchers, the foundation builds sustained expertise in lymphoma research, because nurturing emerging scientists ensures long-term innovation and continuity in the field.
  • Expert-Guided Research Prioritization
    methodology: expert_peer_review
    By leveraging a Scientific Advisory Board of global experts to review and select high-impact research projects, the foundation ensures funding is directed toward the most innovative and promising lymphoma research, because expert peer review increases scientific rigor and impact.
  • Patient-Centered Education Model
    methodology: patient_centered_education
    By delivering expert-led, accessible educational resources—through virtual, in-person, and self-paced formats—the foundation improves patient decision-making and engagement, because tailored, timely information empowers patients and care partners to navigate complex treatment journeys with greater confidence.